News
Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...
8d
Zacks Investment Research on MSNHere is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
Novavax (NASDAQ:NVAX) was on track to end its seventh consecutive session in the red territory after shares of the company ...
The stock's rise snapped a seven-day losing streak.
Shares of Novavax Inc. NVAX slid 2.28% to $6.85 Wednesday, on what proved to be an all-around mixed trading session for the ...
5d
Zacks.com on MSNNovavax (NVAX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.
Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...
Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...
Novavax also has a vaccine finder on its website. To use it, type in your ZIP code in the small search box, and pharmacies nearby with the vaccine in stock will be displayed.
Novavax stock has plummeted from $290 a share in February 2021 to around $50 recently. The FDA finally appears poised to authorize the company's vaccine, however.
Why Novavax’s vaccine was authorized 2 years into the pandemic Novavax CEO Stanley Erck discusses his company’s COVID-19 vaccine, which was authorized by the FDA this week.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results